SAN JOSE, Calif., April 23, 2020 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment, prevention, and diagnosis of cancer and
infectious diseases, today announced the publication of a
peer-reviewed journal article in Biomarker Insights.
The article, entitled "Detecting Prostate Cancer Using Pattern
Recognition Neural Networks with Flow Cytometry-Based
Immunophenotyping in At-Risk Men," supports the use of Anixa's
Cchek™ early cancer detection technology as a tool to improve
prostate cancer detection and reduce unnecessary biopsies.
Cchek™ is an artificial intelligence (AI)-driven platform
developed as a simple blood test to detect solid tumors by
screening for the body's immune response to the presence of a
malignancy. The technology uses flow cytometry of white blood
cells and AI to identify tumor-bearing patients.
The journal article, co-authored by Anixa with collaborators
from the Wistar Institute, the MD Anderson Cancer Center at Cooper
and the Cooper Medical School of Rowan
University and New Jersey Urology, LLC, highlights study
data demonstrating Cchek's™ ability to distinguish healthy men from
high-risk prostate cancer patients with a sensitivity (the ability
to identify patients with the disease) of 96.6% and a specificity
(the ability to correctly identify healthy subjects) of 87.5%.
In addition, Cchek™ demonstrated an ability to distinguish,
among men scheduled for biopsy, those with high-risk prostate
cancer from those with benign conditions or low-grade cancer, for
which surgery is not required and a biopsy is unnecessary.
Amit Kumar, Ph.D., Chief
Executive of Anixa and the study's senior author, stated, "The
Anixa team is excited by the publication of our scientific paper in
Biomarker Insights. Our goal with Cchek™ has been to
develop an inexpensive blood test that accurately detects the
presence of cancer by measuring the body's immune response.
Based on these results, Cchek™ appears able to not only
accurately identify men with prostate cancer, but also distinguish,
with considerable accuracy, men who are disease free."
The Biomarker Insights article is available to view at
the following link:
The journal article's lead author is George A. Dominguez, Ph.D., Senior Clinical
Research Scientist at Anixa. The co-authors are Alexander T. Polo, John
Roop, Anthony J. Campisi and
Amit Kumar, Ph.D. from Anixa
Biosciences; Dmitry I. Gabrilovich,
MD, Ph.D from the Wistar Institute; Robert
A. Somer, MD from the MD Anderson Cancer Center at Cooper
and the Cooper Medical School of Rowan
University; and Adam D. Perzin, MD from New Jersey Urology,
Cchek™ is an early cancer detection
technology, that measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral
blood. The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method that offers improved
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The CLIA validated Cchek™ Prostate Cancer Confirmation
(Cchek™ PCC) test, is the first commercial test developed with
the Cchek™ liquid biopsy technology.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. The
company's diagnostic portfolio consists of Cchek™, a liquid biopsy
technology for early detection of solid tumors based on the body's
immune response to the presence of a malignancy. Anixa
continually examines emerging technologies in complementary fields
for further development and commercialization. Additional
information is available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
Johanna Bennett (Media)
View original content to download
SOURCE Anixa Biosciences, Inc.